-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎Editor of WuXi AppTec Content Team On November 22, 2021, Affimed announced that its cord blood-derived natural killer cell therapy was pre-combined with the innate cell engager (ICE) AFM13.
Positive results were obtained in a phase 1 clinical trial in pre-treated Hodgkin and non-Hodgkin's lymphoma patients
.
The test results showed that among the 12 patients who received the recommended dose of treatment, all patients achieved objective remission, with a complete remission rate of 42%
.
Natural killer (NK) cells are the innate immune cells that exist in the human body.
Like common T cells, they have the ability to attack tumor cells, but the mechanism of killing tumor cells is different
.
On the basis of CAR-T therapy to successfully treat blood diseases, many biomedical companies are also developing and using natural killer cells to treat cancer.
At present, most companies adopt the method to develop CAR-NK cells, which is to integrate antigen chimeric receptors ( CAR) is expressed on NK cells, allowing them to target tumor cells
.
Affimed's strategy is to combine natural killer cells that have no targeting ability with the innate cell adaptor that gives them the ability to target
.
Part of this compound can bind to CD16A on the surface of NK cells and macrophages, which can activate these cells without the need for costimulatory signals
.
Another part of it can bind to specific antigens on the surface of tumor cells, thereby recruiting NK cells and macrophages to the vicinity of tumor cells and activating them to produce killing effects
.
One advantage of this molecule is that it can be "tailored" to target different tumor targets, thereby giving NK cells the ability to treat different types of cancer
.
▲The mode of action of the combined use of innate cell binders and NK cells (picture source: Affimed official website) As of October 31, 2021, a total of 18 CD30-positive relapsed/refractory Hodgkin’s lymphomas (n=16) and non- Hodgkin's lymphoma patients (n=2) received different doses of this innovative treatment
.
The treatment dose of cohort 1 is 1×10^6 NK cells/kg (n=3); cohort 2 is 1×10^7 NK cells/kg (n=3); cohort 3 is 1×10^8 NK cells Cells/kg (n=12)
.
The results of the trial showed that of the 18 patients, 16 patients achieved objective remissions, including 7 complete remissions (CR) and 9 partial remissions (PR)
.
Among the patients who received the recommended second-stage dose (1×10^8 NK cells/kg) treatment, all patients achieved remission after the first treatment cycle, including 5 CR and 7 PR
.
In terms of safety, the treatment combination showed good tolerance
.
No serious adverse events such as cytokine release syndrome, neurotoxicity syndrome or graft-versus-host disease were observed
.
Dr.
Andreas Harstrick, Chief Medical Officer of Affimed, said: “The patients who participated in this study received a large number of pre-treatments with a median of 6 lines, and the disease progressed after treatment
.
The remissions observed in these difficult-to-treat patients The rate is encouraging and we also see the good safety of the combination
.
This is important because many of these patients cannot tolerate overly intense treatments because they have already received a lot of treatment
.
Through the verification of these preliminary data, we see the potential of combining innate cell adaptor molecules with NK cells
.
"Reference: [1]AffimedAnnounces100%ObjectiveResponseRateatHighestDoseinPhase1-2StudyofCordBlood-derivedNaturalKillerCellsPre-complexedwithInnateCellEngagerAFM13forCD30-positiveLymphomas.
RetrievedNovember22,2021,from https:// dose-in-phase-1-2-study-of-cord-blood-derived-natural-killer-cells-pre-complexed-with-innate-cell-engager-afm13-for-cd30-positive-lymphomas/disclaimer : WuXi AppTec's content team focuses on introducing global biomedical health research progress
.
This article is for information exchange purposes only.
The opinions
in the
article do not represent WuXi AppTec's position, nor does it mean that WuXi AppTec supports or opposes the views in the article .
This article is not a treatment plan recommendation.
.
If you need guidance on the treatment plan, please go to a regular hospital for treatment
.
Positive results were obtained in a phase 1 clinical trial in pre-treated Hodgkin and non-Hodgkin's lymphoma patients
.
The test results showed that among the 12 patients who received the recommended dose of treatment, all patients achieved objective remission, with a complete remission rate of 42%
.
Natural killer (NK) cells are the innate immune cells that exist in the human body.
Like common T cells, they have the ability to attack tumor cells, but the mechanism of killing tumor cells is different
.
On the basis of CAR-T therapy to successfully treat blood diseases, many biomedical companies are also developing and using natural killer cells to treat cancer.
At present, most companies adopt the method to develop CAR-NK cells, which is to integrate antigen chimeric receptors ( CAR) is expressed on NK cells, allowing them to target tumor cells
.
Affimed's strategy is to combine natural killer cells that have no targeting ability with the innate cell adaptor that gives them the ability to target
.
Part of this compound can bind to CD16A on the surface of NK cells and macrophages, which can activate these cells without the need for costimulatory signals
.
Another part of it can bind to specific antigens on the surface of tumor cells, thereby recruiting NK cells and macrophages to the vicinity of tumor cells and activating them to produce killing effects
.
One advantage of this molecule is that it can be "tailored" to target different tumor targets, thereby giving NK cells the ability to treat different types of cancer
.
▲The mode of action of the combined use of innate cell binders and NK cells (picture source: Affimed official website) As of October 31, 2021, a total of 18 CD30-positive relapsed/refractory Hodgkin’s lymphomas (n=16) and non- Hodgkin's lymphoma patients (n=2) received different doses of this innovative treatment
.
The treatment dose of cohort 1 is 1×10^6 NK cells/kg (n=3); cohort 2 is 1×10^7 NK cells/kg (n=3); cohort 3 is 1×10^8 NK cells Cells/kg (n=12)
.
The results of the trial showed that of the 18 patients, 16 patients achieved objective remissions, including 7 complete remissions (CR) and 9 partial remissions (PR)
.
Among the patients who received the recommended second-stage dose (1×10^8 NK cells/kg) treatment, all patients achieved remission after the first treatment cycle, including 5 CR and 7 PR
.
In terms of safety, the treatment combination showed good tolerance
.
No serious adverse events such as cytokine release syndrome, neurotoxicity syndrome or graft-versus-host disease were observed
.
Dr.
Andreas Harstrick, Chief Medical Officer of Affimed, said: “The patients who participated in this study received a large number of pre-treatments with a median of 6 lines, and the disease progressed after treatment
.
The remissions observed in these difficult-to-treat patients The rate is encouraging and we also see the good safety of the combination
.
This is important because many of these patients cannot tolerate overly intense treatments because they have already received a lot of treatment
.
Through the verification of these preliminary data, we see the potential of combining innate cell adaptor molecules with NK cells
.
"Reference: [1]AffimedAnnounces100%ObjectiveResponseRateatHighestDoseinPhase1-2StudyofCordBlood-derivedNaturalKillerCellsPre-complexedwithInnateCellEngagerAFM13forCD30-positiveLymphomas.
RetrievedNovember22,2021,from https:// dose-in-phase-1-2-study-of-cord-blood-derived-natural-killer-cells-pre-complexed-with-innate-cell-engager-afm13-for-cd30-positive-lymphomas/disclaimer : WuXi AppTec's content team focuses on introducing global biomedical health research progress
.
This article is for information exchange purposes only.
The opinions
in the
article do not represent WuXi AppTec's position, nor does it mean that WuXi AppTec supports or opposes the views in the article .
This article is not a treatment plan recommendation.
.
If you need guidance on the treatment plan, please go to a regular hospital for treatment
.
